Legend Biotech launches $225M public offering

What's the deal? Legend Biotech, the Nasdaq-listed cell therapy company, has launched a $225M underwritten public offering of American Depositary Shares. Morgan StanleyDealroom has a profile for this one. Try Dealroom →, Jefferies, Citigroup, and Deutsche Bank Securities are serving as joint book-running managers.

Each ADS represents two ordinary shares of the company. Legend Biotech also intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold at the offering price.

Why now? Legend Biotech is the largest standalone cell therapy company, with over 3,000 employees and a flagship product — CARVYKTI, a one-time CAR-T treatment for relapsed or refractory multiple myeloma developed and marketed with Johnson & JohnsonDealroom has a profile for this one. Try Dealroom →. The company has been expanding patient access and building out its end-to-end cell therapy platform from its US base.

Fresh capital could help fund that expansion and advance its pipeline of cell therapy modalities.

What could go wrong? The offering is subject to market conditions, and there's no guarantee it will close on the proposed terms — or at all. Cell therapy remains a capital-intensive field, and Legend Biotech faces competition from larger pharma players investing heavily in the space.

The signal: As the largest standalone cell therapy company, Legend Biotech's ability to tap public markets for $225M underscores that investor confidence in late-stage CAR-T platforms remains intact — even amid a choppy biotech fundraising climate. The blue-chip underwriting syndicate, led by Morgan Stanley and Jefferies, suggests institutional demand is strong enough to support further commercial scale-up of CARVYKTI and pipeline expansion beyond multiple myeloma.

Read more: marketscreener.com